Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Current Deferred Revenue (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Current Deferred Revenue data on record, last reported at $2.0 million in Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 62.94% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, down 62.94%, while the annual FY2025 figure was $2.0 million, 62.94% down from the prior year.
  • Current Deferred Revenue reached $2.0 million in Q4 2025 per PTCT's latest filing, up from $1.7 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $12.8 million in Q1 2025 and bottomed at $214000.0 in Q1 2023.
  • Average Current Deferred Revenue over 5 years is $3.7 million, with a median of $1.8 million recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: plummeted 81.73% in 2021, then surged 587.27% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $1.9 million in 2021, then decreased by 28.89% to $1.4 million in 2022, then tumbled by 40.71% to $801000.0 in 2023, then soared by 587.27% to $5.5 million in 2024, then crashed by 62.94% to $2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $2.0 million in Q4 2025, $1.7 million in Q3 2025, and $9.8 million in Q2 2025.